cabiralizumab (BMS-986227) / Ono Pharma, BMS 
Welcome,         Profile    Billing    Logout  
 0 Diseases   2 Trials   2 Trials   142 News 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
cabiralizumab (BMS-986227) / Ono Pharma, BMS
NCT03927105: Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma

Completed
2
4
US
Nivolumab, Opdivo, BMS-936558, MDX1106, cabiralizumab, BMS-986227, FPA008
University of Michigan Rogel Cancer Center, Bristol-Myers Squibb
Peripheral T Cell Lymphoma
11/19
07/23
NCT03336216 / 2018-000339-28: A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer

Checkmark From trial in combination trial with cabiralizumab in advanced pancreatic cancer
Feb 2020 - Feb 2020: From trial in combination trial with cabiralizumab in advanced pancreatic cancer
Completed
2
205
Europe, Canada, Japan, US, RoW
Cabiralizumab, BMS-986227, FPA008, Nab-paclitaxel, Abraxane, Onivyde, irinotecan liposome, Nivolumab, Opdivo, BMS-936558, Fluorouracil, 5-Fluorouracil, Gemcitabine, Oxaliplatin, Leucovorin, Irinotecan Hydrochloride
Bristol-Myers Squibb
Advanced Pancreatic Cancer
06/23
06/23
Spark2, NCT04848116: Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck Ca

Recruiting
2
24
US
Nivolumab, BMS-936558, HuMax-IL8, BMS-986253
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bristol-Myers Squibb
Head and Neck Squamous Cell Carcinoma
04/25
04/26
NCT04050462: Nivolumab Combined With BMS-986253 in HCC Patients

Active, not recruiting
2
23
US
Nivolumab 240 mg IV every 2 weeks + Cabiralizumab 4 mg/kg IV every 2 weeks, Nivolumab 240 mg IV every 2 weeks + BMS-986253 1200 mg IV every 2 weeks, Nivolumab 240 mg IV every 2 weeks
NYU Langone Health
Hepatocellular Carcinoma
12/24
12/25
NCT04331067: Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer

Active, not recruiting
1/2
15
US
Paclitaxel, Taxol, Carboplatin, Paraplatin, Nivolumab, Opdivo, BMS-936558, Cabiralizumab, BMS-986227, Tumor biopsy, Bone marrow, Blood draw
Washington University School of Medicine, Bristol-Myers Squibb
Triple Negative Breast Cancer
03/23
05/26
C4-MOSART, NCT03431948: Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for Cancer

Completed
1
60
US
Nivolumab, OPDIVO, BMS-936558, Cabiralizumab, BMS-986227, FPA008, Urelumab, BMS-663513, Stereotactic Body Radiation Therapy
University of Chicago, Bristol-Myers Squibb
Cancer
02/20
04/22
NCT03502330: APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma

Hourglass May 2019 - Dec 2019 : From P1/1b trial in combination with APX005M and cabiralizumab
Completed
1
42
US
APX005M, Cabiralizumab, Nivolumab
Yale University, Bristol-Myers Squibb, Apexigen America, Inc., National Cancer Institute (NCI)
Advanced Melanoma, Non-small Cell Lung Cancer, Renal Cell Carcinoma
01/22
05/24

Download Options